GC녹십자 그룹 내 세포·유전자치료제 전문 개발사 지씨셀(GC Cell)의 R&D pipeline, 연구개발, CDMO, 상업화/유통 역량 소개
Checkpoint Therapeutics (NASDAQ:CKPT) and South Korea's GC Cell will collaborate on a combination treatment of the former's cosibelimab, an anti-PD-L1 antibody, and the latter's Immuncell-LC, a T-cell therapy. At the outset, the work will focus on in vitro studies to examine synergistic...
“As the first-ever overseas event for a cell therapy created in Korea, this symposium marks is a significant milestone for the industry,” said a GC Cell spokesperson. “By building trust and visibility in the Indonesian market, we are accelerating the global commercialization of Imm...
T-cell lymphoma is a type of lymphoma that occurs in lymphoid tissues outside of lymph nodes, affecting NK cells and T-cells. It is relatively more common in Asian countries, including Korea, than in the U.S. or Europe. This condition is broadly categorized into cutaneous T-cell lymphoma ...
GC Cell, a Korean biotech company, announced on Mar. 28th that it had held the 12th General Shareholders' Meeting at GC Biopharma R&D Center in Yongin, Gyeonggi-do of South Korea and resolved some major agenda items, including the appointment of inside d
South Korea'sfirst CAR-NK cell therapy cleared for human trials inAustraliaand domestically; Cancer Moonshot participant GC Cell partnering with medical AI leader Lunit to collaborate on AB-201 clinical development YONGIN,South Koreaand SYDNEY,Jan. 8, 2024/PR...
GC KOREA CO., LTD. GC DENTAL (SUZHOU) CO., LTD. KLEMA Dentalprodukte GmbH CREATION Relationship with Society GC, as a dental manufacturer, considers excellence in its core business to be the most important mission. We will grow into a more trusted company by interacting with society through...
检查站,GC Cell评估联合癌症疗法 Checkpoint Therapeutics(CKPT) stem(STEM)0.4422-8.41% Checkpoint Therapeutics (NASDAQ:CKPT) and South Korea's GC Cell will collaborate on a combination treatment of the former's cosibelimab, an anti-PD-L1 antibody, and the latter's Immuncell-LC, a T-cell ...
Backed by such findings, GC Cell stressed that it is actively pursuing both Korean and international expansion. “We plan to apply for national health insurance coverage in Korea this year, with the goal of review by the Cancer Disease Review Committee of the Health Insurance Review and Assessmen...
As Korea's top biopharmaceutical company, GC has been leading the market in the field of blood products and vaccines for the past 50 years. In addition, GC is focused on developing innovative new drugs such as cell therapy products and orphan drugs, and aims to enter the global market based...